Cargando…

Impaired alveolar macrophage 11β-hydroxysteroid dehydrogenase type 1 reductase activity contributes to increased pulmonary inflammation and mortality in sepsis-related ARDS

BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is a devastating pulmonary inflammatory disorder, commonly precipitated by sepsis. Glucocorticoids are immunomodulatory steroids that can suppress inflammation. Their anti-inflammatory properties within tissues are influenced by their pre-recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahida, Rahul Y., Lax, Siân, Bassford, Christopher R., Scott, Aaron, Parekh, Dhruv, Hardy, Rowan S., Naidu, Babu, Matthay, Michael A., Stewart, Paul M., Cooper, Mark C., Perkins, Gavin D., Thickett, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172463/
https://www.ncbi.nlm.nih.gov/pubmed/37180160
http://dx.doi.org/10.3389/fimmu.2023.1159831
_version_ 1785039619875667968
author Mahida, Rahul Y.
Lax, Siân
Bassford, Christopher R.
Scott, Aaron
Parekh, Dhruv
Hardy, Rowan S.
Naidu, Babu
Matthay, Michael A.
Stewart, Paul M.
Cooper, Mark C.
Perkins, Gavin D.
Thickett, David R.
author_facet Mahida, Rahul Y.
Lax, Siân
Bassford, Christopher R.
Scott, Aaron
Parekh, Dhruv
Hardy, Rowan S.
Naidu, Babu
Matthay, Michael A.
Stewart, Paul M.
Cooper, Mark C.
Perkins, Gavin D.
Thickett, David R.
author_sort Mahida, Rahul Y.
collection PubMed
description BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is a devastating pulmonary inflammatory disorder, commonly precipitated by sepsis. Glucocorticoids are immunomodulatory steroids that can suppress inflammation. Their anti-inflammatory properties within tissues are influenced by their pre-receptor metabolism and amplification from inactive precursors by 11β-hydroxysteroid dehydrogenase type-1 (HSD-1). We hypothesised that in sepsis-related ARDS, alveolar macrophage (AM) HSD-1 activity and glucocorticoid activation are impaired, and associated with greater inflammatory injury and worse outcomes. METHODS: We analysed broncho-alveolar lavage (BAL) and circulating glucocorticoid levels, AM HSD-1 reductase activity and Receptor for Advanced Glycation End-products (RAGE) levels in two cohorts of critically ill sepsis patients, with and without ARDS. AM HSD-1 reductase activity was also measured in lobectomy patients. We assessed inflammatory injury parameters in models of lung injury and sepsis in HSD-1 knockout (KO) and wild type (WT) mice. RESULTS: No difference in serum and BAL cortisol: cortisone ratios are shown between sepsis patients with and without ARDS. Across all sepsis patients, there is no association between BAL cortisol: cortisone ratio and 30-day mortality. However, AM HSD-1 reductase activity is impaired in patients with sepsis-related ARDS, compared to sepsis patients without ARDS and lobectomy patients (0.075 v 0.882 v 0.967 pM/hr/10(6) AMs, p=0.004). Across all sepsis patients (with and without ARDS), impaired AM HSD-1 reductase activity is associated with defective efferocytosis (r=0.804, p=0.008) and increased 30-day mortality. AM HSD-1 reductase activity negatively correlates with BAL RAGE in sepsis patients with ARDS (r=-0.427, p=0.017). Following intra-tracheal lipopolysaccharide (IT-LPS) injury, HSD-1 KO mice demonstrate increased alveolar neutrophil infiltration, apoptotic neutrophil accumulation, alveolar protein permeability and BAL RAGE concentrations compared to WT mice. Caecal Ligation and Puncture (CLP) injury in HSD-1 KO mice results in greater peritoneal apoptotic neutrophil accumulation compared to WT mice. CONCLUSIONS: AM HSD-1 reductase activity does not shape total BAL and serum cortisol: cortisone ratios, however impaired HSD-1 autocrine signalling renders AMs insensitive to the anti-inflammatory effects of local glucocorticoids. This contributes to the decreased efferocytosis, increased BAL RAGE concentrations and mortality seen in sepsis-related ARDS. Upregulation of alveolar HSD-1 activity could restore AM function and improve clinical outcomes in these patients.
format Online
Article
Text
id pubmed-10172463
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101724632023-05-12 Impaired alveolar macrophage 11β-hydroxysteroid dehydrogenase type 1 reductase activity contributes to increased pulmonary inflammation and mortality in sepsis-related ARDS Mahida, Rahul Y. Lax, Siân Bassford, Christopher R. Scott, Aaron Parekh, Dhruv Hardy, Rowan S. Naidu, Babu Matthay, Michael A. Stewart, Paul M. Cooper, Mark C. Perkins, Gavin D. Thickett, David R. Front Immunol Immunology BACKGROUND: Acute Respiratory Distress Syndrome (ARDS) is a devastating pulmonary inflammatory disorder, commonly precipitated by sepsis. Glucocorticoids are immunomodulatory steroids that can suppress inflammation. Their anti-inflammatory properties within tissues are influenced by their pre-receptor metabolism and amplification from inactive precursors by 11β-hydroxysteroid dehydrogenase type-1 (HSD-1). We hypothesised that in sepsis-related ARDS, alveolar macrophage (AM) HSD-1 activity and glucocorticoid activation are impaired, and associated with greater inflammatory injury and worse outcomes. METHODS: We analysed broncho-alveolar lavage (BAL) and circulating glucocorticoid levels, AM HSD-1 reductase activity and Receptor for Advanced Glycation End-products (RAGE) levels in two cohorts of critically ill sepsis patients, with and without ARDS. AM HSD-1 reductase activity was also measured in lobectomy patients. We assessed inflammatory injury parameters in models of lung injury and sepsis in HSD-1 knockout (KO) and wild type (WT) mice. RESULTS: No difference in serum and BAL cortisol: cortisone ratios are shown between sepsis patients with and without ARDS. Across all sepsis patients, there is no association between BAL cortisol: cortisone ratio and 30-day mortality. However, AM HSD-1 reductase activity is impaired in patients with sepsis-related ARDS, compared to sepsis patients without ARDS and lobectomy patients (0.075 v 0.882 v 0.967 pM/hr/10(6) AMs, p=0.004). Across all sepsis patients (with and without ARDS), impaired AM HSD-1 reductase activity is associated with defective efferocytosis (r=0.804, p=0.008) and increased 30-day mortality. AM HSD-1 reductase activity negatively correlates with BAL RAGE in sepsis patients with ARDS (r=-0.427, p=0.017). Following intra-tracheal lipopolysaccharide (IT-LPS) injury, HSD-1 KO mice demonstrate increased alveolar neutrophil infiltration, apoptotic neutrophil accumulation, alveolar protein permeability and BAL RAGE concentrations compared to WT mice. Caecal Ligation and Puncture (CLP) injury in HSD-1 KO mice results in greater peritoneal apoptotic neutrophil accumulation compared to WT mice. CONCLUSIONS: AM HSD-1 reductase activity does not shape total BAL and serum cortisol: cortisone ratios, however impaired HSD-1 autocrine signalling renders AMs insensitive to the anti-inflammatory effects of local glucocorticoids. This contributes to the decreased efferocytosis, increased BAL RAGE concentrations and mortality seen in sepsis-related ARDS. Upregulation of alveolar HSD-1 activity could restore AM function and improve clinical outcomes in these patients. Frontiers Media S.A. 2023-04-27 /pmc/articles/PMC10172463/ /pubmed/37180160 http://dx.doi.org/10.3389/fimmu.2023.1159831 Text en Copyright © 2023 Mahida, Lax, Bassford, Scott, Parekh, Hardy, Naidu, Matthay, Stewart, Cooper, Perkins and Thickett https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Mahida, Rahul Y.
Lax, Siân
Bassford, Christopher R.
Scott, Aaron
Parekh, Dhruv
Hardy, Rowan S.
Naidu, Babu
Matthay, Michael A.
Stewart, Paul M.
Cooper, Mark C.
Perkins, Gavin D.
Thickett, David R.
Impaired alveolar macrophage 11β-hydroxysteroid dehydrogenase type 1 reductase activity contributes to increased pulmonary inflammation and mortality in sepsis-related ARDS
title Impaired alveolar macrophage 11β-hydroxysteroid dehydrogenase type 1 reductase activity contributes to increased pulmonary inflammation and mortality in sepsis-related ARDS
title_full Impaired alveolar macrophage 11β-hydroxysteroid dehydrogenase type 1 reductase activity contributes to increased pulmonary inflammation and mortality in sepsis-related ARDS
title_fullStr Impaired alveolar macrophage 11β-hydroxysteroid dehydrogenase type 1 reductase activity contributes to increased pulmonary inflammation and mortality in sepsis-related ARDS
title_full_unstemmed Impaired alveolar macrophage 11β-hydroxysteroid dehydrogenase type 1 reductase activity contributes to increased pulmonary inflammation and mortality in sepsis-related ARDS
title_short Impaired alveolar macrophage 11β-hydroxysteroid dehydrogenase type 1 reductase activity contributes to increased pulmonary inflammation and mortality in sepsis-related ARDS
title_sort impaired alveolar macrophage 11β-hydroxysteroid dehydrogenase type 1 reductase activity contributes to increased pulmonary inflammation and mortality in sepsis-related ards
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172463/
https://www.ncbi.nlm.nih.gov/pubmed/37180160
http://dx.doi.org/10.3389/fimmu.2023.1159831
work_keys_str_mv AT mahidarahuly impairedalveolarmacrophage11bhydroxysteroiddehydrogenasetype1reductaseactivitycontributestoincreasedpulmonaryinflammationandmortalityinsepsisrelatedards
AT laxsian impairedalveolarmacrophage11bhydroxysteroiddehydrogenasetype1reductaseactivitycontributestoincreasedpulmonaryinflammationandmortalityinsepsisrelatedards
AT bassfordchristopherr impairedalveolarmacrophage11bhydroxysteroiddehydrogenasetype1reductaseactivitycontributestoincreasedpulmonaryinflammationandmortalityinsepsisrelatedards
AT scottaaron impairedalveolarmacrophage11bhydroxysteroiddehydrogenasetype1reductaseactivitycontributestoincreasedpulmonaryinflammationandmortalityinsepsisrelatedards
AT parekhdhruv impairedalveolarmacrophage11bhydroxysteroiddehydrogenasetype1reductaseactivitycontributestoincreasedpulmonaryinflammationandmortalityinsepsisrelatedards
AT hardyrowans impairedalveolarmacrophage11bhydroxysteroiddehydrogenasetype1reductaseactivitycontributestoincreasedpulmonaryinflammationandmortalityinsepsisrelatedards
AT naidubabu impairedalveolarmacrophage11bhydroxysteroiddehydrogenasetype1reductaseactivitycontributestoincreasedpulmonaryinflammationandmortalityinsepsisrelatedards
AT matthaymichaela impairedalveolarmacrophage11bhydroxysteroiddehydrogenasetype1reductaseactivitycontributestoincreasedpulmonaryinflammationandmortalityinsepsisrelatedards
AT stewartpaulm impairedalveolarmacrophage11bhydroxysteroiddehydrogenasetype1reductaseactivitycontributestoincreasedpulmonaryinflammationandmortalityinsepsisrelatedards
AT coopermarkc impairedalveolarmacrophage11bhydroxysteroiddehydrogenasetype1reductaseactivitycontributestoincreasedpulmonaryinflammationandmortalityinsepsisrelatedards
AT perkinsgavind impairedalveolarmacrophage11bhydroxysteroiddehydrogenasetype1reductaseactivitycontributestoincreasedpulmonaryinflammationandmortalityinsepsisrelatedards
AT thickettdavidr impairedalveolarmacrophage11bhydroxysteroiddehydrogenasetype1reductaseactivitycontributestoincreasedpulmonaryinflammationandmortalityinsepsisrelatedards